This Article Full Text Full Text (PDF) All Versions of this Article: 91/6/2047    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reiter, E. O. Articles by Ranke, M. B. Search for Related Content PubMed PubMed Citation Articles by Reiter, E. O. Articles by Ranke, M. B. Pubmed/NCBI databases Substance via MeSH Related Collections Neuroendocrinology and Pituitary

Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database

Baystate Children’s Hospital, Tufts University School of Medicine (E.O.R.), Springfield, Massachusetts 01199; Department of Child Health, Royal Manchester Children’s Hospital (D.A.P.), Manchester M27 4HA, United Kingdom; Pfizer (P.W.), S-19190 Stockholm, Sweden; Pediatric Growth Research Center, University of Gothenburg (K.A.-W.), S40439 Gothenburg, Sweden; and Pediatric Endocrinology Section, University Children’s Hospital (M.B.R.), Tubingen D-72076, Germany

Address all correspondence and requests for reprints to: Dr. Edward O. Reiter, Baystate Medical Center Children’s Hospital, Tufts University School of Medicine, Springfield, Massachusetts 01199. E-mail: edward.reiter{at}bhs.org.

Context: Treatment with GH has been used to correct the growth deficit in children with GH deficiency (GHD). Although successful in increasing height velocity, such treatment often falls short of helping patients achieve full genetic height potential.

Objective: This study set out to analyze near-final height (FH) data from a cohort of GH-treated children with idiopathic GHD.

Design, Setting, and Participants: Of 1258 evaluable patients in the Pfizer International Growth Database (KIGS) with GHD, 980 were of Caucasian origin, and 278 were of Japanese origin; 747 had isolated GHD (IGHD), and 511 had multiple pituitary hormone deficiencies (MPHD).

Main Outcome Measures: Near-FH, relation to midparental height, and factors predictive of growth outcomes were the main outcome measures.

Results: Median height SD scores (SDS) at the start of treatment were –2.4 (IGHD) and –2.9 (MPHD) for Caucasian males and –2.6 (IGHD) and –3.4 (MPHD) for females, respectively; comparable starting heights were –2.9 (IGHD) and –3.6 (MPHD) for Japanese males and –3.3 (IGHD) and –4.0 (MPHD) for females, respectively. Corresponding near-adult height SDS after GH treatment were –0.8 (IGHD) and –0.7 (MPHD) for Caucasian males and –1.0 (IGHD) and –1.1 (MPHD) for females, respectively; and –1.6 (IGHD) and –1.9 (MPHD) for Japanese males and –2.1 (IGHD) and –1.8 (MPHD) for females, respectively. Differences between near-adult height and midparental height ranged between –0.6 and +0.2 SDS for the various groups, with the closest approximation to MPH occurring in Japanese males with MPHD. The first-year increase in height SDS and prepubertal height gain was highly correlated with total height gain, confirming the importance of treatment before pubertal onset.

Conclusions: It is possible to achieve FH within the midparental height range in patients with idiopathic GHD treated from an early age with GH, but absolute height outcomes remain in the lower part of the normal range. Patients with MPHD generally had a slightly better long-term height outcome.

This article has been cited by other articles:

				B. Raz, M. Janner, V. Petkovic, D. Lochmatter, A. Eble, M. T. Dattani, P. C. Hindmarsh, C. E. Fluck, and P. E. Mullis Influence of Growth Hormone (GH) Receptor Deletion of Exon 3 and Full-Length Isoforms on GH Response and Final Height in Patients with Severe GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 974 - 980. [Abstract] [Full Text] [PDF]

				P. F. Collett-Solberg, M. Misra, and on behalf of the Drug and Therapeutics Committee o The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 10 - 18. [Abstract] [Full Text] [PDF]

				G. Gelwane, C. Garel, D. Chevenne, P. Armoogum, D. Simon, P. Czernichow, and J. Leger Subnormal Serum Insulin-Like Growth Factor-I Levels in Young Adults with Childhood-Onset Nonacquired Growth Hormone (GH) Deficiency Who Recover Normal GH Secretion May Indicate Less Severe but Persistent Pituitary Failure J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3788 - 3795. [Abstract] [Full Text] [PDF]

				S. Bechtold, P. Ripperger, R. D. Pozza, W. Bonfig, R. Hafner, H. Michels, and H. P. Schwarz Growth Hormone Increases Final Height in Patients with Juvenile Idiopathic Arthritis: Data from a Randomized Controlled Study J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3013 - 3018. [Abstract] [Full Text] [PDF]

				M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega Prediction of Adult Height in Growth-Hormone-Treated Children with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 925 - 931. [Abstract] [Full Text] [PDF]

				S. K. Varma Growing Numbers for Idiopathic Short Stature Growth Hormone Therapy AAP Grand Rounds, February 1, 2007; 17(2): 19 - 20. [Full Text] [PDF]

				S. Zucchini, P. Pirazzoli, F. Baronio, M. Gennari, M. O. Bal, A. Balsamo, S. Gualandi, and A. Cicognani Effect on Adult Height of Pubertal Growth Hormone Retesting and Withdrawal of Therapy in Patients with Previously Diagnosed Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4271 - 4276. [Abstract] [Full Text] [PDF]